Bod Science has the GF Score of 12, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Bod Science
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Bod Science (ASX:BOD) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Bod Science GF Score Related Terms
ASX:BOD vs ZTS: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's GF Score distribution charts can be found below:
* The bar in red indicates where Bod Science's GF Score falls into.
Bod Science (ASX:BOD) has a GF Score of 12 as of Jul. 01, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bod Science and its competitors. This is 14% below median its historical median of 14.00. Over the past decade, Bod Science's GF Score has ranged from 6.00 to 53.00.
Is Bod Science's GF Score too high?
Bod Science's current GF Score of 12 is 14% below median its 10-year median of 14.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 53.00. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's GF Score compare to ZTS?
Bod Science's GF Score of 12 can be compared against companies in the Drug Manufacturers industry. Historically, Bod Science's own GF Score has ranged from 6.00 to 53.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bod Science and its competitors. Bod Science's current GF Score is 12, which is 14% below median its own 10-year median of 14.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current GF Score of 12. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current GF Score is 12, which is 14% below median its 10-year median of 14.00. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current GF Score is 12 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
GF Score: 12 (14% below median its 10-year median of 14.00)
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 